Lori Kleiman, PA
Medical · Newark, DENPI 1942403332
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $747, 4.6 times the $162 reported in 2021.
Across 90 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$234
- Neurelis, Inc.$165
- UCB, Inc.$127
- Biogen$97
- Lilly USA, LLC$89
- Johnson & Johnson$82
- plus $1K from 30 others
What the payments were for
- Food & beverage$1,847100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $234 |
| Neurelis, Inc. | 9 | $165 |
| UCB, Inc. | 5 | $127 |
| Biogen | 5 | $97 |
| Lilly USA, LLC | 5 | $89 |
| Johnson & Johnson | 4 | $82 |
| TG Therapeutics, Inc. | 2 | $70 |
| Neurocrine Biosciences, Inc. | 3 | $67 |
| Argenx US, Inc. | 2 | $62 |
| Lundbeck LLC | 3 | $60 |
| AbbVie | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Saluda Medical Americas, Inc. | 2 | $50 |
| AstraZeneca(2 entities) | 2 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Nevro Corp. | 2 | $39 |
| SK Life Science, Inc. | 2 | $38 |
| Pfizer | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Amgen | 2 | $31 |
| Genentech USA, Inc. | 1 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Appliedvr Inc | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Vertex | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Protega Pharmaceutials Inc | 1 | $12 |
How this compares
$1,847 in reported general payments places this provider in the 80th percentile of 73 medical providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 73 | $56,208 |
| Buprenorphine | 68 | $19,025 |
| ButransBuprenorphine | 13 | $6,960 |
| Lidocaine | 49 | $3,508 |
| Gabapentin | 242 | $3,312 |
| Tramadol Hcl ErTramadol Hcl | 48 | $2,660 |
| Pregabalin | 135 | $2,449 |
| Oxycodone Hcl | 146 | $2,052 |
| Tramadol Hcl | 183 | $1,924 |
| Tizanidine Hcl | 120 | $1,139 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $553 |
| Duloxetine Hcl | 22 | $552 |
| Cyclobenzaprine Hcl | 48 | $477 |
| Morphine Sulfate | 19 | $396 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 30 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $40 | $56,20873 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 medical providers in Delaware.
Other medical in Newark
- Gwen DalphonNewark$116K
- Stephanie CarlinoNewark$9K
- Michele ComptonNewark$4K
- Shraddha PatelNewark$3K
- Robert KondosNewark$3K
- Sherri CampbellNewark$977
- Amanda MageeNewark$967
- Lauren TavaniNewark$850
- Madison GoudyNewark$658
- Sarah StraubNewark$622
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.